Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-positive status confers therapeutic sensitivity to Carboplatin, Docetaxel, Trastuzumab in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab in combination with carboplatin and docetaxel (TCH) - 21 days for reimbursement as a treamtent option for the adjuvant treatment of HER2 positive early breast cancer.
This statement is based on a regulatory approval from the Health Service Executive:
Adjuvant treatment HER2 positive early breast cancer